These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 6818899)

  • 21. Gentamicin and amikacin---an in vitro comparison using 1000 clinical isolates.
    Forgan-Smith WR; McSweeney RJ
    Aust N Z J Med; 1978 Aug; 8(4):383-6. PubMed ID: 282852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior activity of N-formimidoyl thienamycin against gentamicin-resistant Pseudomonas aeruginosa.
    Michael PR; Alford RH; McGee ZA
    Antimicrob Agents Chemother; 1981 Nov; 20(5):702-4. PubMed ID: 6798926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-formimidoyl thienamycin: in vitro comparison with cefoxitin and tobramycin against clinical, bacterial isolates.
    Digranes A; Dibb WL; Benonisen E
    Acta Pathol Microbiol Immunol Scand B; 1983 Apr; 91(2):141-4. PubMed ID: 6603093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.
    Horadam VW; Smilack JD; Montgomery CL; Werringloer J
    Antimicrob Agents Chemother; 1980 Oct; 18(4):557-61. PubMed ID: 6934707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. UK-18892, a new aminoglycoside: an in vitro study.
    Wise R; Andrews JM
    Antimicrob Agents Chemother; 1978 Aug; 14(2):228-33. PubMed ID: 100050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative activity of habekacin and 4 other aminoglycosides against gram-negative bacilli. Evolution of resistance].
    Reynaud AE; Coude du Foresto B; Derriennic M; Courtieu AL
    Pathol Biol (Paris); 1988 May; 36(5):435-8. PubMed ID: 3136424
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of cefotaxime-aminoglycoside combinations against aminoglycoside-resistant Pseudomonas.
    Murray PR
    Antimicrob Agents Chemother; 1980 Mar; 17(3):474-6. PubMed ID: 6252830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.
    Kesado T; Hashizume T; Asahi Y
    Antimicrob Agents Chemother; 1980 Jun; 17(6):912-7. PubMed ID: 6931548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergism between N-formimidoyl thienamycin and gentamicin or tobramycin against enterococci.
    Watanakunakorn C; Tisone JC
    Antimicrob Agents Chemother; 1982 Dec; 22(6):1082-3. PubMed ID: 6818900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of amikacin and ten other aminoglycoside antibiotics against gentamicin-resistant bacterial strains.
    Reyonolds AV; Hamilton-Miller JM; Brumfitt W
    J Infect Dis; 1976 Nov; 134 SUPPL():S291-6. PubMed ID: 62815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of N-formimidoyl thienamycin and cephalosporins against isolates from nosocomially acquired bacteremia.
    Gutiérrez-Núñez J; Harrington PT; Ramirez-Ronda CH
    Antimicrob Agents Chemother; 1982 Mar; 21(3):509-12. PubMed ID: 6954876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cefoxitin: synergism with aminoglycosides in vitro.
    Une T; Osada Y; Ogawa H
    Arzneimittelforschung; 1981; 31(5):761-4. PubMed ID: 6791664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Susceptibility of recently isolated bacteria to amikacin in vitro: comparisons with four other aminoglycoside antibiotics.
    Finland M; Garner C; Wilcox C; Sabath LD
    J Infect Dis; 1976 Nov; 134 SUPPL():S297-307. PubMed ID: 825588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC; Wennersten C; Kunz LJ; Poitras JW
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of netilmicin, gentamicin, and amikacin.
    Kantor RJ; Norden CW
    Antimicrob Agents Chemother; 1977 Jan; 11(1):126-31. PubMed ID: 402104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
    Schassan HH
    Infection; 1976; 4(2):35-41. PubMed ID: 789246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fortimicin A: collaborative in vitro susceptibility. Comparison with amikacin and gentamicin against 11,840 clinical bacterial isolates.
    Jones RN; Barry AL; Fuchs PC; Gavan TL; Sommers HM; Gerlach EH
    Antimicrob Agents Chemother; 1979 Dec; 16(6):823-8. PubMed ID: 533262
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of clinically important bacteria to amikacin: correlation of results of broth dilution and disk sensitivity tests and effect of medium composition.
    Linzenmeier G; Naumann P; Neussel H; Rosin H
    J Infect Dis; 1976 Nov; 134 SUPPL():S262-70. PubMed ID: 825584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of multiresistance on the minimal inhibitory concentration of N-formimidoyl thienamycin and 6 comparing substances against P. aeruginosa and 4 Enterobacteriaceae species].
    Schröter G; Schrettenbrunner A; Strenzel I
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1983 Feb; 253(4):531-43. PubMed ID: 6407236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.